ONCOLOGY Vol 16 No 3
-
-
FDA Approves Pegfilgrastim to Protect Against Chemotherapy-Related Neutropenia
-
Rubitecan Active in Hematologic Malignancies
-
The Role of PC-SPES, Selenium, and Vitamin E in Prostate Cancer
-
Current Approaches to the Treatment of Well-Differentiated Thyroid Cancer
-
Durable Responses Reported With Radioimmunotherapy in Low-Grade Non-Hodgkin’s Lymphoma
-
Mantle Cell Lymphoma: High Rates of Complete Remission and Prolonged Failure-Free Survival With Rituximab/Hyper-CVAD Without Stem Cell Transplant
-
Tolerance of Treatment Subsequent to Front-Line Tositumomab/Iodine-131 Tositumomab in Patients With Follicular Lymphoma
-
COMMENTARY
-
Single-Agent Rituximab in Early-Stage Chronic Lymphocytic Leukemia
-
Recruitment for Trial of Adjuvant Trastuzumab Under Way
-
Tolerance of Treatment Subsequent to Front-Line Tositumomab/Iodine-131 Tositumomab in Patients With Follicular Lymphoma
-
COMMENTARY
-
Successful Treatment of Pure Red Cell Aplasia With Rituximab in Patients With Chronic Lymphocytic Leukemia
-
Rituximab in the Treatment of Acquired Factor VIII Inhibitors
-
Current Approaches to the Treatment of Well-Differentiated Thyroid Cancer
-
A Phase II Study of Apolizumab, a Humanized Monoclonal Antibody, in Patients With Relapsed or Refractory Follicular, Small Lymphocytic, or Marginal Zone/MALT B-Cell Lymphoma
-
Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia
-
Support for New Medicare Pay Formula
-
Phase II Trial of CHOP Followed by Rituximab, a Chimeric Monoclonal Anti-CD20 Antibody, for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma: SWOG 9800
-
Treatment of Acute Myelogenous Leukemia
-
Management of Fatigue in the Cancer Patient
-
A Randomized Trial of Fludarabine and Mitoxantrone Plus Rituximab vs CHOP Plus Rituximab as First-Line Treatment in Patients With Follicular Lymphoma
-
Rituximab Plus CHOP in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: An Update of the GELA Study
-
Irinotecan-Containing Regimen Improves Survival in Small-Cell Lung Cancer
-
Management of Fatigue in the Cancer Patient
-
Subsequent Chemotherapy Regimens Well Tolerated After Radioimmunotherapy With Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma
-
The Role of PC-SPES, Selenium, and Vitamin E in Prostate Cancer
-
Current Clinical Trials of Molecularly Targeted Agents in Children With Cancer
-
COMMENTARY
-
Therapeutic Activity of Humanized Anti-CD20 Monoclonal Antibody and Polymorphism in IgG FcReceptor FcgRIIIa Gene
-
Monoclonal Antibodies That Mimic the Action of Intravenous Immunoglobulin Can Inhibit Immune Thrombocytopenia
-
Treatment of Acquired Factor VIII Deficiency With Rituximab
-
Phase III Trial of Virulizin for Advanced Pancreatic Cancer
-
Phase II Study of Subcutaneous Alemtuzumab (Campath) Therapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
-
Cost-Effectiveness of Rituximab in Treatment of Diffuse Large B-Cell Lymphoma
-
Rituximab Treatment in Patients With Immune Thrombocytopenic Purpura
-
Rituximab May Overcome bcl-2-Associated Chemotherapy Resistance in Untreated Diffuse Large B-Cell Lymphomas
-
Rituximab Kills Freshly Isolated B-NHL and B-CLL More Efficiently by Complement Than by ADCC In Vitro: Role of CD20 Expression Levels and of the CD55 and CD59 Complement Inhibitors
-
Recurrent Multicentric Glioblastoma Multiforme Responds to Thalidomide and Chemotherapy
-
Treatment of Acute Myelogenous Leukemia
-
Phase II Study of Rituximab in the Treatment of Cladribine-Failed Patients With Hairy Cell Leukemia
-
Concurrent Rituximab and Fludarabine Has a Higher Complete Response Rate Than Sequential Treatment in Untreated Chronic Lymphocytic Leukemia Patients: Results From CALGB 9712
-
Combined Fludarabine, Cyclophosphamide, and Rituximab Achieves a High Complete Remission Rate as Initial Treatment for Chronic Lymphocytic Leukemia
-
Hematopoietic Stem Cell Transplantation in Lymphoma Patients Receiving Prior Therapy With Tositumomab/Iodine-131 Tositumomab
-
COMMENTARY
-
Management of Fatigue in the Cancer Patient
-
Phase II Study of Rituximab Plus Fludarabine in Patients With Low-Grade Lymphoma: Final Report
-
Management of Fatigue in the Cancer Patient
-
Commentary (Cheson): Rituximab in the Treatment of Autoimmune Hemolytic Anemia
-
Response to Treatment With Rituximab in a Patient With Acquired von Willebrand Disease
-
Antibody-Targeted Chemotherapy Included in NCCN Oncology Practice Guidelines
-
COMMENTARY
-
COMMENTARY
-
A Phase II Trial of CHOP Followed by Tositumomab/Iodine-131 Tositumomab for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas (SWOG 9911)
-
bcl-2 Antisense as Monotherapy for Refractory Chronic Lymphocytic Leukemia
-
The Addition of Rituximab to Combination Chemotherapy With Fludarabine, Cyclophosphamide, Mitoxantrone—Results of a Prospective Randomized Comparison by the German Low Grade Study Group
-
Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type)
-
bcl-2 Antisense Induces Apoptosis and Potentiates Activity of Both Cytotoxic Chemotherapy and Rituximab in Primary Chronic Lymphocytic Leukemia Cells
-
COMMENTARY
-
Vinorelbine/Trastuzumab Produces Synergistic Effects in HER2-Positive Metastatic Breast Cancer
-
Monoclonal Antibodies in Hematologic Malignancies: Research and Clinical Developments
-
Treatment of Acute Myelogenous Leukemia
-
Textbook of Medical Oncology, 2nd Edition
-
Update of Results of the Combination of Fludarabine, Cyclophosphamide, and Rituximab for Previously Treated Patients With Chronic Lymphocytic Leukemia
-
COMMENTARY
-
Combination Monoclonal Antibody Therapy for Lymphoma: Treatment With Epratuzumab (Anti-CD22) and Rituximab (Anti-CD20) Is Well Tolerated
-
Phase I Study of Rituximab and Alemtuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
-
Rituximab as First-Line and Maintenance Therapy for Patients With Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia
-
An Exploratory Study of the Combination of Monoclonal Antibodies Alemtuzumab and Rituximab in the Treatment of CD52- and CD20-Positive Chronic Lymphoid Disorders
-
Current Approaches to the Treatment of Well-Differentiated Thyroid Cancer
-
Progression-Free Survival After Six Years (Median) Follow-Up of the First Clinical Trial of Rituximab/CHOP Chemoimmunotherapy
-
The Role of PC-SPES, Selenium, and Vitamin E in Prostate Cancer
-
More Money for Breast/Cervical Screening
|
|
